FI83325B - Foerfarande foer framstaellning av 7- substituerade 3-(5-cyklopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-metyl -6-oxo-4h-imidazo(1,5-a)(1,4) bensodiazepiner. - Google Patents
Foerfarande foer framstaellning av 7- substituerade 3-(5-cyklopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-metyl -6-oxo-4h-imidazo(1,5-a)(1,4) bensodiazepiner. Download PDFInfo
- Publication number
- FI83325B FI83325B FI862062A FI862062A FI83325B FI 83325 B FI83325 B FI 83325B FI 862062 A FI862062 A FI 862062A FI 862062 A FI862062 A FI 862062A FI 83325 B FI83325 B FI 83325B
- Authority
- FI
- Finland
- Prior art keywords
- compound
- formula
- dihydro
- compounds
- cyclopropyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 14
- -1 5-CYCLOPROPYL-1,2,4-OXADIAZOL-3-YL Chemical class 0.000 title claims description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 77
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 5
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 4
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- GUJAGMICFDYKNR-UHFFFAOYSA-N 1,4-benzodiazepine Chemical class N1C=CN=CC2=CC=CC=C12 GUJAGMICFDYKNR-UHFFFAOYSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 235000015243 ice cream Nutrition 0.000 claims 1
- 150000002894 organic compounds Chemical class 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 abstract description 17
- 210000003169 central nervous system Anatomy 0.000 abstract description 4
- 230000036461 convulsion Effects 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 230000000949 anxiolytic effect Effects 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 102000004300 GABA-A Receptors Human genes 0.000 description 10
- 108090000839 GABA-A Receptors Proteins 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 230000009870 specific binding Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000015114 central nervous system disease Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 229960005152 pentetrazol Drugs 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- BGHGVAKKIBOJGS-UHFFFAOYSA-N 5-cyclopropyl-3-(isocyanomethyl)-1,2,4-oxadiazole Chemical compound [C-]#[N+]CC1=NOC(C2CC2)=N1 BGHGVAKKIBOJGS-UHFFFAOYSA-N 0.000 description 4
- 239000001961 anticonvulsive agent Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229960002200 flunitrazepam Drugs 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- WUHLVXDDBHWHLQ-UHFFFAOYSA-N pentazole Chemical compound N=1N=NNN=1 WUHLVXDDBHWHLQ-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- SADOJDRAQISFAK-UHFFFAOYSA-N 4-(1H-1,2-benzodiazepin-3-yl)oxadiazole Chemical class C1=CC2=CC=CC=C2NN=C1C1=CON=N1 SADOJDRAQISFAK-UHFFFAOYSA-N 0.000 description 2
- FXAXGHCUXZNILI-UHFFFAOYSA-N 6-bromo-4-methyl-1,3-dihydro-1,4-benzodiazepine-2,5-dione Chemical compound O=C1N(C)CC(=O)NC2=CC=CC(Br)=C21 FXAXGHCUXZNILI-UHFFFAOYSA-N 0.000 description 2
- OMYWEBATCXKXLI-UHFFFAOYSA-N 7-chloro-n'-hydroxy-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboximidamide Chemical compound O=C1N(C)CC2=C(C(N)=NO)N=CN2C2=CC=CC(Cl)=C21 OMYWEBATCXKXLI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010053398 Clonic convulsion Diseases 0.000 description 2
- 102000005915 GABA Receptors Human genes 0.000 description 2
- 108010005551 GABA Receptors Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000011785 NMRI mouse Methods 0.000 description 2
- 206010034759 Petit mal epilepsy Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 206010043994 Tonic convulsion Diseases 0.000 description 2
- 208000003554 absence epilepsy Diseases 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 2
- 229960003120 clonazepam Drugs 0.000 description 2
- 230000002566 clonic effect Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000002555 ionophore Substances 0.000 description 2
- 230000000236 ionophoric effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- OYPIXUZKTODLAC-UHFFFAOYSA-N n-[(5-cyclopropyl-1,2,4-oxadiazol-3-yl)methyl]formamide Chemical compound O=CNCC1=NOC(C2CC2)=N1 OYPIXUZKTODLAC-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 210000004129 prosencephalon Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012289 standard assay Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
- ZVAPWJGRRUHKGP-UHFFFAOYSA-N 1h-1,5-benzodiazepine Chemical class N1C=CC=NC2=CC=CC=C12 ZVAPWJGRRUHKGP-UHFFFAOYSA-N 0.000 description 1
- GJSWKWBEBGBNLT-UHFFFAOYSA-N 2,4,11-triazatetracyclo[11.4.0.02,6.07,11]heptadeca-1(17),3,5,8,13,15-hexaen-12-one Chemical compound O=C1N2CC=CC2C2=CN=CN2C2=CC=CC=C12 GJSWKWBEBGBNLT-UHFFFAOYSA-N 0.000 description 1
- ZSJUKDUHDOMINL-UHFFFAOYSA-N 3-(1H-1,2-benzodiazepin-3-yl)-1,2,4-oxadiazole Chemical class C1=CC2=CC=CC=C2NN=C1C=1N=CON=1 ZSJUKDUHDOMINL-UHFFFAOYSA-N 0.000 description 1
- OTDNRJFVBKYTDJ-UHFFFAOYSA-N 3-morpholin-4-yl-1-pyrrolidin-1-ylpiperidin-2-one Chemical compound O1CCN(CC1)C1C(N(CCC1)N1CCCC1)=O OTDNRJFVBKYTDJ-UHFFFAOYSA-N 0.000 description 1
- XHBHKHBUALFEOU-UHFFFAOYSA-N 4,5-dihydroimidazo[1,5-a][1,4]benzodiazepin-6-one Chemical class O=C1NCC2=CN=CN2C2=CC=CC=C12 XHBHKHBUALFEOU-UHFFFAOYSA-N 0.000 description 1
- OUVUFAZUKYKNCJ-UHFFFAOYSA-N 4-imidazo[4,5-i][1,2]benzodiazepin-3-yloxadiazole Chemical class N=1N=C2C3=NC=NC3=CC=C2C=CC=1C1=CON=N1 OUVUFAZUKYKNCJ-UHFFFAOYSA-N 0.000 description 1
- BAQNPAZPDWIUHZ-UHFFFAOYSA-N 4-methyl-2,5-dioxo-1,3-dihydro-1,4-benzodiazepine-6-carbonitrile Chemical compound O=C1N(C)CC(=O)NC2=CC=CC(C#N)=C21 BAQNPAZPDWIUHZ-UHFFFAOYSA-N 0.000 description 1
- NJLZFBSRXZEKNR-UHFFFAOYSA-N 6-fluoro-4-methyl-1,3-dihydro-1,4-benzodiazepine-2,5-dione Chemical compound O=C1N(C)CC(=O)NC2=CC=CC(F)=C21 NJLZFBSRXZEKNR-UHFFFAOYSA-N 0.000 description 1
- ZAMMFLQIVBVQMQ-UHFFFAOYSA-N 7-chloro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carbonitrile Chemical compound O=C1N(C)CC2=C(C#N)N=CN2C2=CC=CC(Cl)=C21 ZAMMFLQIVBVQMQ-UHFFFAOYSA-N 0.000 description 1
- BFBMOZLXLDVEKZ-UHFFFAOYSA-N CN1CC(NC2=C(C1=O)C(=CC=C2)Cl)=O.C2(CC2)C2=NC(=NO2)C=2N=CN1C2CN(C(C2=C1C=CC=C2Cl)=O)C Chemical compound CN1CC(NC2=C(C1=O)C(=CC=C2)Cl)=O.C2(CC2)C2=NC(=NO2)C=2N=CN1C2CN(C(C2=C1C=CC=C2Cl)=O)C BFBMOZLXLDVEKZ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- LTKUGDREISBAHW-UHFFFAOYSA-N O=C1N2CCCC2C2=CN=CN2C2=CC=CC=C12 Chemical class O=C1N2CCCC2C2=CN=CN2C2=CC=CC=C12 LTKUGDREISBAHW-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000000573 anti-seizure effect Effects 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- LDDOSDVZPSGLFZ-UHFFFAOYSA-N ethyl cyclopropanecarboxylate Chemical compound CCOC(=O)C1CC1 LDDOSDVZPSGLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000004866 oxadiazoles Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Polyesters Or Polycarbonates (AREA)
- Polyethers (AREA)
- Phenolic Resins Or Amino Resins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (2)
1. Förfarande för framställning av 7-substituerade 3-(5-cyk-lopropyl-i,2,4-oxadiazol-3-yl)-5,6-dihydro-5-metyl-6-oxo-4H-imidazo(1,5-a)(1,4)bensodiazepiner användbara som ISkemedel och med formeln (VII) ψΐ ..... X O CHj i vilken X Sr Cl, Br eller F, och deras farmaceutiskt acceptable syraadditionssalter, kännetecknat därav, att a) en förening med formeln (Vili) O-CH ΓοΤ^Ν ) (viii> ' I \h, x o 3 i vilken X betecknar detsamma som ovan, omsSttes med NH2OH för framställning av en förening med formeln (IX) NOH f")-/ (IXI c§r > 2 * r c“3 i vilken X betecknar detsamma som ovan, och den sä erhällna föreningen omsSttes med en förening med formeln 23 83325 D>- coci för framställning av en förening med formeln (VII), eller b) en förening med formeln (X) i vilken X betecknar detsamma som ovan och Y är en avgäende grupp, företredesvis -0P(0)(0-etyl)2, omsättes företrädesvis under alkaliska betingelser, företrädesvis i närvaro av ett organiskt lösningsmedel och företrädesvis vid en temperatur av -40eC - 30°C, med en förening med formeln CH-CH, N för framställning av en förening med formeln (VII).
2. Förfarande enligt patentkravet 1, kännetecknat därav, att man framställer 3-(5-cyklopropyl-l,2,4-oxadiazol- 3-yl)-5,6-dihydro-5-metyl-6-oxo-7-brom-4H-imidazo(1,5-a)(1,4)-bensodiazepin.
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK220485A DK220485D0 (da) | 1985-05-17 | 1985-05-17 | Nye oxadiazolylimidazobenzodiazepinderivater samt fremgangsmaade tilfremstilling heraf |
| DK220485 | 1985-05-17 | ||
| DK365985 | 1985-08-12 | ||
| DK365985A DK365985D0 (da) | 1985-08-12 | 1985-08-12 | Nye oxadiazolylimidazobenzodiazepinderivater samt fremgangsmaade tilfremstilling heraf |
| DK476985A DK476985D0 (da) | 1985-10-17 | 1985-10-17 | Fremgangsmaade til fremstilling af oxadiazolylderivater af imidazobenzodiazepiner og mellemprodukt til brug ved fremgangsmaaden |
| DK476985 | 1985-10-17 | ||
| DK599485A DK599485D0 (da) | 1985-12-20 | 1985-12-20 | Nye oxadiazolylimidazobenzodiazepinderivater samt fremgangsmaade til fremstilling heraf |
| DK599485 | 1985-12-20 | ||
| US81673286 | 1986-01-06 | ||
| US06/816,732 US4622320A (en) | 1985-05-17 | 1986-01-06 | Oxadiazolylimidazobenzodiazepine, compositions, and method |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI862062A0 FI862062A0 (fi) | 1986-05-16 |
| FI862062L FI862062L (fi) | 1986-11-18 |
| FI83325B true FI83325B (fi) | 1991-03-15 |
| FI83325C FI83325C (sv) | 1991-06-25 |
Family
ID=27512886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI862062A FI83325C (sv) | 1985-05-17 | 1986-05-16 | Förfarande för framställning av 7-substituerade 3-(5-cyklopropyl-1,2,4 -oxadiazol-3-yl)-5,6-dihydro-5-metyl-6-oxo-4H-imidazo(1,5-a)(1,4)benso diazepiner |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0202441B1 (sv) |
| AT (1) | ATE38671T1 (sv) |
| DE (2) | DE202441T1 (sv) |
| DK (1) | DK154837C (sv) |
| FI (1) | FI83325C (sv) |
| GR (1) | GR861261B (sv) |
| IE (1) | IE59495B1 (sv) |
| IL (1) | IL78791A (sv) |
| NO (1) | NO162859C (sv) |
| NZ (1) | NZ216203A (sv) |
| PT (1) | PT82593B (sv) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK174086D0 (da) * | 1986-04-16 | 1986-04-16 | Ferrosan As | Nye benzodiazepinderivater samt fremgangsmaade til fremstilling af samme |
| FI880814A7 (fi) * | 1987-03-10 | 1988-09-11 | Hoffmann La Roche | Imidazodiazepin-derivat. |
| DK155524C (da) * | 1987-03-18 | 1989-09-11 | Ferrosan As | Kondenserede imidazolderivater og farmaceutiske praeparater indeholdende disse |
| FI101305B1 (sv) * | 1996-03-18 | 1998-05-29 | Map Medical Technologies Oy | Radiofarmaceutiska preparationer av radiojoderade bentsodiazepinanaloger och deras användning i diagnostik |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK151808C (da) * | 1982-11-16 | 1988-06-20 | Ferrosan As | Analogifremgangsmaade til fremstilling af oxadiazolylimidazo-oe1,4aa-benzodiazepinderivater |
| CA1252462A (en) * | 1984-01-19 | 1989-04-11 | Walter Hunkeler | Imidazodiazepine derivatives |
-
1986
- 1986-04-04 DE DE198686104605T patent/DE202441T1/de active Pending
- 1986-04-04 DE DE8686104605T patent/DE3661197D1/de not_active Expired
- 1986-04-04 AT AT86104605T patent/ATE38671T1/de not_active IP Right Cessation
- 1986-04-04 EP EP86104605A patent/EP0202441B1/en not_active Expired
- 1986-05-14 GR GR861261A patent/GR861261B/el unknown
- 1986-05-15 IL IL78791A patent/IL78791A/xx not_active IP Right Cessation
- 1986-05-16 NZ NZ216203A patent/NZ216203A/xx unknown
- 1986-05-16 PT PT82593A patent/PT82593B/pt not_active IP Right Cessation
- 1986-05-16 DK DK231586A patent/DK154837C/da not_active IP Right Cessation
- 1986-05-16 IE IE130786A patent/IE59495B1/en not_active IP Right Cessation
- 1986-05-16 FI FI862062A patent/FI83325C/sv not_active IP Right Cessation
- 1986-05-16 NO NO86861953A patent/NO162859C/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE38671T1 (de) | 1988-12-15 |
| IE59495B1 (en) | 1994-02-23 |
| GR861261B (en) | 1986-09-10 |
| DK154837C (da) | 1989-05-16 |
| DK231586D0 (da) | 1986-05-16 |
| IL78791A (en) | 1991-01-31 |
| EP0202441B1 (en) | 1988-11-17 |
| NO861953L (no) | 1986-11-18 |
| PT82593A (en) | 1986-06-01 |
| EP0202441A1 (en) | 1986-11-26 |
| DE3661197D1 (en) | 1988-12-22 |
| DE202441T1 (de) | 1987-03-19 |
| PT82593B (pt) | 1988-03-03 |
| NZ216203A (en) | 1989-02-24 |
| DK154837B (da) | 1988-12-27 |
| IL78791A0 (en) | 1986-08-31 |
| FI862062L (fi) | 1986-11-18 |
| FI862062A0 (fi) | 1986-05-16 |
| NO162859C (no) | 1990-02-28 |
| IE861307L (en) | 1986-11-17 |
| DK231586A (da) | 1986-11-18 |
| FI83325C (sv) | 1991-06-25 |
| NO162859B (no) | 1989-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI82050C (sv) | Förfarande för framställning som läkemedel användbara 3-oxadiazolylder ivat av imidazol(1,5-a)kinoxaliner och 1-oxdiazolylderivat av imidazo( 1,5-a)pyrrolo(2,1-c)kinoxaliner | |
| CN101466714B (zh) | 作为hm74a激动剂的嘌呤酮衍生物 | |
| AU2002226674B2 (en) | Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient | |
| FI92700B (sv) | Förfarande för framställning av nya terapeutiskt användbara 5-oxo-4,5-dihydro-imidazo/1,5-a/kinazolinderivat | |
| AU2007260852A1 (en) | Purinone derivatives as HM74a agonists | |
| KR940009784B1 (ko) | 벤조디아제핀 유도체의 제조방법 | |
| FI93836B (sv) | Förfarande för framställning av nya terapeutiskt användbara 4,5-dihydro-4-oxo-5-isopropyl-imidazo/1,5-a/pyrido/2,3-e/pyrazinderivat | |
| FI82049B (fi) | Foerfarande foer framstaellning av saosom laekemedel anvaendbar 3-(5-cyklopropyl-1,2,4-oxadiazol-3-yl) 5,6-dihydro-5-metyl-6-oxo-4h-imidazo-(1,5-a)(1,4)bensodiazepin. | |
| FI83871C (sv) | Förfarande för framställning av såsom psykofarmaceutiska medel användb ara 4,5-dihydro-5-oxo-imidazo(1,5-a)kinazolinderivat | |
| JPH09508635A (ja) | アザ環式誘導体 | |
| EP0197282A1 (en) | Novel oxadiazolyl imidazobenzodiazepine derivatives and methods of preparing such compounds | |
| FI83325B (fi) | Foerfarande foer framstaellning av 7- substituerade 3-(5-cyklopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-metyl -6-oxo-4h-imidazo(1,5-a)(1,4) bensodiazepiner. | |
| HU197011B (en) | Process for producing new imidazo- and triazolo-1,4-benzodiazepines and pharmaceuticals comprising the same | |
| KR20050098931A (ko) | 옥시토신 작용제 및 바소프레신 길항제로서의 벤즈아미드유도체 | |
| FI91759C (sv) | Förfarande för framställning av terapeutiskt användbara imidazo/1,5-a/tieno/3,2-d/- och -/3,2-e/pyrimidiner | |
| CA1256865A (en) | Oxadiazolylimidazobenzodiazepine, compositions, and method iii | |
| CN117136051A (zh) | Adamts抑制剂的前药、其制备方法和医药用途 | |
| JPH0329795B2 (sv) | ||
| DK154142B (da) | Imidazo(1,5-a)quinoxalinforbindelse samt praeparat indeholdende samme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Transfer of assignment of patent |
Owner name: NOVO NORDISK A/S |
|
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: NOVO NORDISK A/S |